Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico / Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: Report of one case
Rev. méd. Chile
; 133(6): 681-684, jun. 2005.
Article
em Es
| LILACS
| ID: lil-429123
Biblioteca responsável:
BR1.1
ABSTRACT
New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m2 for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Fatores Imunológicos
/
Lúpus Eritematoso Sistêmico
/
Anticorpos Monoclonais
Limite:
Adolescent
/
Female
/
Humans
Idioma:
Es
Revista:
Rev. méd. Chile
Assunto da revista:
MEDICINA
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Chile
País de publicação:
Chile